

Treating problem drug use

Thomas Clausen, MD, PhD (Norway)

Tuesday 24th October 2017



Treatment of problem drug use

Thomas Clausen Ivar Skeie (Christian Tjagvad)

Norwegian Centre for Addiction Research thomas.clausen@medisin.uio.no

Agenda

✓ Addiction a chronic disorder

- ✓ Harm reduction and rehabilitation/recovery
- ✓ Comorbidity
- ✓ Use and misuse of medications in OMT, and mechanisms of fatal overdose


➤ What should be done?

Addiction

Drug addiction is a chronic, often relapsing brain disease that causes compulsive drug seeking and use, despite harmful consequences to the drug addicted person and those around them

Drug addiction leads to changes in the structure and function of the brain

The Vicious Circle of Addiction













Opioid using persons A range of subpopulations









Treatment of a chronic condition The example og RA


- ✓ The main treatment goals with rheumatoid arthritis are to control the condition and slow or stop the progression
- ✓ Treatment is usually a <u>multifaceted program</u> that consists of medications, occupational or physical therapy, and regular exercise. Sometimes, surgery is needed.
- ✓ <u>Early, aggressive treatment</u> is key to good results. With today's treatments, joint damage can be slowed or stopped in many cases.
- ✓ The <u>treatment must be tailored</u> to each patient's individual case, including the severity of the condition, the effectiveness of specific therapies, and the occurrence of side effects.
- ✓ It is important to work with a healthcare provider to create an effective and acceptable plan for treating RA.

Treatment of addiction A condition with varying intensity


✓ Aim: control condition and reduce risk

- > Offer early, comprehensive treatment
- > Multifaceted approach
- > Tailored interventions, adopted to comorbidities
- > Health care provider part of interdisciplinary process
- Long-term approach and plan
- > Include strategies to handle relapse
- > Adjust treatment intensity to symptom intensity

Varying intensity with time



Mortality before, during and after OMT in Norway



Clausen T. et al. Drug and Alcohol Dependence, 2008, Mortality prior to, during and after opioid maintenance treatment (OMT)


Fatal overdoses!

√8/10 of fatal overdoses caused by opioids (heroin, morphine, methadone, fentanyl etc)

> Respiratory depression and oxygen deficiency




Overdoses in Europe; on a rise



EMCDDA: European drug report 2017

Overdoses in the Nordics; (2012)

K.W. Simonsen et al./Forensic Science International 248 (2015) 172–180



15-65 år

Responses:

Norwegian National Overdose Strategy 2014 – 2017





Norwegian Directorate of Health

Sure you can quit drugs but first you have to survive!

https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/145/National-overdose-strategy-2014-2017-IS-0418EN.pdf

National overdose prevention strategy

- ✓ Aims at reducing numbers of deaths annually
 - Long-term 0-vision

- > Multidimensional strategy:
 - Improve access to evidence based treatment (OMT)
 - Take-home Naloxone distribution
 - Encourage "SWITCH" from injection to inhalation
 - Improve knowledge and practices in municipalities
 - Included funding (also for evaluation)

https://helsedirektoratet.no/folkehelse/psykisk-helse-og-rus/overdose https://helsedirektoratet.no/publikasjoner/nasjonal-overdosestrategi-20142017

Nasal naloxone in Norway




A systematic approach

- ✓ A range of services
 - Coordinated "A treatment system"
 - Integrated Cater for comorbidities
 - Tailored to needs Primarily in community
 - Long-term Varying intensity


- > Treatment goals:
 - > Reduced risk
 - >Improved health
 - ➤ Improved quality of life

Opioid Drug treatment A comprehensive model



Conclusions Dimensions of addiction care

- > Access to care
- > Control while in treatment
- Quality of care



- Quality of care includes adoption to users needs
- ➤ Includes active support towards meaningful daily activity and abstinent networks
- Combinations of psychosocial interventions and medications



Thank you!



www.twist-train.eu



The TWIST project is co-funded by grant Nº 759685 under the European Union's Justice Programme – Drugs Initiatives. The content of this presentation represents the views of the author only and is his/her sole responsibility. The European Commission does not accept any responsibility for use that may be made of the information it contains.